Prognostic classification of breast ductal carcinoma-in-situ

The Lancet

Volumn 345, Issue 8958, 1995, Pages 1154-1157

  Poller, D N ^a   Barth, A ^b   Slamon, D J ^c   Silverstein, M J ^d   Gierson, E D ^d   Coburn, W J ^e   Waisman, J R ^f   Gamagami, P ^g   Lewinsky, B S ^h  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Breast Center   (United States)

^e The Breast Center and Divisions Surgical Pathology The Breast Center ^*  (United States)

^f The Breast Center and Divisions Surgical Medical Oncology The Breast Center ^*  (United States)

^g Breast Imaging ^*  (United States)

^h Radiation Therapy The Breast Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL TRIAL; COMEDO; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TISSUE NECROSIS;

EID: 0029021632     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)90982-6     Document Type: Article

References (30)

1. Chromosomal aneuploidy in proliferative breast disease
2. Loss of heterozygosity in ductal carcinoma in situ of the breast
3. Duct carcinoma in situ: pathology and treatment
4. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation
5. Ductal carcinoma in situ of the female breast: short-term results of a prospective nationwide study
6. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression
7. Subclinical ductal carcinoma in situ of the breast: treatment by local excision and surveillance alone
8. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization
9. Ductal carcinoma in situ: a proposal for a new classification
10. Carcinoma in situ (CIS)
11. Intraductal carcinoma
12. Borderline epithelial lesions of the breast
13. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
14. Consistency of histopathological reporting of breast lesions detected by breast screening findings of the UK national external quality assessment (EQA) scheme
15. Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
16. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ
17. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ
18. The classification of ductal carcinoma in situ and its association with biological markers
19. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
20. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data
21. P53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein
22. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast
23. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotem
24. Evaluation of infiltrating ductal carcinomas with a DCIS component correlation of the histologic type of the in situ component with grade of the infiltrating component
25. Status of breast cancer prognostication based on histopathologic data
26. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications
27. Can intraductal breast carcinoma be excised completely by local excision?
28. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer